Peptides Australian doctors review
Profiles of clinical peptides an AHPRA-registered doctor at a partner clinic may review on a case-by-case basis. Registered GLP-1 medicines use standard ARTG-product prescriptions; eligible unapproved medicines require a separate regulatory pathway.
In short: this hub explains each peptide's regulatory status in Australia, what the evidence does and does not show, and which TGA access pathway applies. It is educational information, not a treatment recommendation.
Or browse the quick A–Z glossaryBPC-157
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Read profile GH secretagogue blendCJC-1295 + Ipamorelin
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Read profile GH secretagogueIpamorelin
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Read profile Weight managementAOD-9604
Evidence limitations and individual safety require clinical assessment. Registration and lawful supply must be checked; this information is not a treatment recommendation.
Read profile GLP-1 / GIP weight managementTirzepatide
Dual GIP and GLP-1 receptor agonist; registered prescription products only.
Read profile Copper peptide — skin & repairGHK-Cu
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Read profile Mitochondrial peptide — metabolicMOTS-c
16-amino-acid mitochondrial-derived peptide investigated for metabolic and insulin-sensitivity support.
Read profile Unapproved peptide fragmentTB-500
Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.
Read profile